- Home
- LGN vs VKTX Comparison
LGN vs VKTX Comparison
Compare LGN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGN | VKTX |
|---|---|---|
| Founded | 1963 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | LGN | VKTX |
|---|---|---|
| Price | $50.91 | $33.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $44.90 | ★ $88.00 |
| AVG Volume (30 Days) | 856.7K | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.13 | N/A |
| Revenue Next Year | $42.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.31 | $18.92 |
| 52 Week High | $58.00 | $43.15 |
Technical Indicators
Market Signals| Indicator | LGN | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 53.89 |
| Support Level | $42.97 | $30.73 |
| Resistance Level | $52.50 | $35.66 |
| Average True Range (ATR) | 3.45 | 1.67 |
| MACD | -0.24 | 0.18 |
| Stochastic Oscillator | 41.98 | 60.03 |
Price Performance
Historical ComparisonAbout LGN Legence Corp.
Legence Corp is a provider of engineering, installation and maintenance services for mission-critical systems in buildings. It focuses on high-growth sectors that have technically demanding buildings, including technology, life sciences, healthcare and education. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting and building controls in existing facilities to make them more energy efficient and sustainable.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.